Amedisys Shares Climb 1.6% as Trading Volume Surges 320% to $340M, Ranking 342nd in Market Activity

Amedisys (AMED) rose 1.60% on August 7, 2025, with a trading volume of $340 million, a 320.09% increase from the previous day, ranking 342nd in market activity. The stock’s performance coincided with a major regulatory development as the U.S. Department of Justice (DOJ) announced a settlement to resolve antitrust concerns over UnitedHealth Group’s $3.3 billion acquisition of Amedisys.

Under the agreement, UnitedHealth’s Optum unit will divest 164 home health and hospice locations, including one affiliated palliative care facility, across 19 states—accounting for approximately $528 million in annual revenue. The DOJ also imposed a $1.1 million civil penalty on Amedisys for failing to disclose missing information during the merger review. The settlement aims to preserve competition in the home health services market, with the divestitures to be supervised by a monitor to ensure compliance.

The deal, initially challenged by the DOJ in 2024 over antitrust risks, now requires judicial approval. Amedisys and UnitedHealth have agreed to the terms, which include mandatory divestitures to third-party buyers, such as BrightSpring Health Services and The Pennant Group. The resolution marks a significant step toward finalizing the acquisition, which UnitedHealth has described as a strategic move to enhance value-based care in home health and hospice services.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.